Allergan’s recent developments
Allergan (AGN) is developing a variety of products through internal programs as well as in collaboration with other companies. A few of the products it currently has under development are Cenicriviroc, Atogepant, Bimatoprost SR, Ubrogepant, Abicipar, Rapastinel, and Sarecycline.
The chart above shows a few recent developments at Allergan.
The developments at Allergan in July and August have included the following updates:
- On August 8, Allergan announced that it had appointed Michael E. Greenberg, PhD, a neurobiology expert, to its board of directors. Dr. Greenberg holds nearly 35 years of experience in scientific discoveries in neurobiology and is the Nathan Marsh Pusey Professor of Neurobiology at Harvard University. He also coleads the Allen Discovery Center for Human Brain Development at Harvard Medical School.
- On August 6, Allergan and Editas Medicine (EDIT) announced that Allergan had exercised its option to develop and commercialize EDIT-101 globally for the treatment of Leber congenital amaurosis 10 (or LCA10). Allergan has paid $15 million to Editas in conjunction with the exercise of the option, and Editas will receive an additional $25 million once the FDA accepts the Investigational New Drug Application for EDIT-101.
- On July 23, the FDA granted a Fast Track designation for AGN-241751, an investigational drug for the treatment of major depressive disorder.
- On July 19, Allergan and Molecular Partners announced positive top line results from two clinical trials, SEQUOIA and CEDAR, for the drug abicipar. Both studies demonstrated that the eight-week and 12-week treatment regimens had met the prespecified primary end points of noninferiority to the drug ranibizumab.